Jan. 25, 2012
-- Sanofi Pasteur is the world's largest company devoted solely to the making of vaccines. With a self-described corporate mission of “protecting and improving human health” and a workforce of over 12,500 people, Sanofi has helped to develop many groundbreaking vaccines and spends over $1,500,000 a day on research and development. While Sanofi Pasteur has been responsible for many vaccine innovations over the years, seven vaccines in particular stand out for their widespread use and effectiveness:
Approved in 2002 by the Food and Drug Administration, Fluzone is the commercial name for the company's influenza vaccine. The vaccine is categorized as a split virus due to the fact that it cannot cause influenza and is administered in a single dose by intramuscular injection. Sanofi also offers two additional unique flu vaccines. Fluzone HD is a high dose flu vaccine offering a higher level of protection intended for those over 65 years of age. Seniors and small children are at the highest risk for complication resulting from the flu. Fluzone ID uses a microneedle that is only 1.5mm long and of a gauge so small that the ID needle fits inside the standard flu injection needle. It is for those 18-64 years of age. Flu vaccine is the vaccine most often rejected by Americans. Fluzone ID may help some overcome that rejection.
Adacel is an active immunization booster designed to prevent tetanus, diphtheria, and pertussis in persons aged 11 to 64.
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenza type b. Specifically designed for young children, Pentacel is administered in a four dose series for children aged six months to five years.
Similar to Pentacel, Daptacel is designed for children and is indicated for active immunization against diphtheria, tetanus and pertussis as a five dose series in infants and children 6 weeks through 6 years of age. The vaccine is administered in a series of five treatments at 2, 4, 6 and 15-20 months of age, and at 4-6 years.
The Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis. The vaccine is approved for use in individuals 9 months through 55 years of age and is administered in a single dose for children less than two years of age and two doses spaced three months apart for all others.
ActHIB is specifically designed for children ages 2 to 18 months of age. The vaccine is administered in a series four treatments and provides protection against Haemophilus influenzae type b (Hib), a type of bacteria that can cause potentially life-threatening diseases.
7. IPOL: The IPOL vaccine is indicated for polio in children over 6 months of age and adults who are deemed at high risk for contracting polio. The vaccine is administered is administered in a series of four injections.
Through their commitment of protecting and improving human life and dedication to research, Sanofi Pasteur has established itself as a leading vaccine manufacturer. The seven vaccines mentioned here have done a great deal to help thousands of lives across the world and no doubt many more in the future. From influenza to polio, Sanofi Pasteur's innovations have done a great deal to create vaccines that are cutting edge, safe, and effective for each life that depends on them.
# # #
Physicians’ Alliance of America (PAA) is a non-profit group purchasing organization. We use the purchasing power of over 27,000 physicians from all 50 states (and D.C.) to negotiate discounts and preferred terms for the goods and services practices use every day.
From vaccine discounts to medical equipment, we offer free access to over 70 vendor partners covering essentially all aspects of practice operations. Learn more about PAA by visiting our website at http://www.physall.com